Clinical trials for Imaging biomarkers

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44334 clinical trials with a EudraCT protocol, of which 7366 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (736)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

736 result(s) found for: Imaging biomarkers. Displaying page 1 of 37.

EudraCT Number: 2021-000070-29	Sponsor Protocol Number: 74668	Start Date*: 2022-09-15
Sponsor Name:VU University Medical Center
Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
Medical condition: Pelizaeus-Merzbacher disease
Disease:
Population Age: Infants and toddlers, Children, Under 18		Gender: Male
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2013-004671-12	Sponsor Protocol Number: s55892	Start Date*: 2014-06-20
Sponsor Name:University of Leuven
Full Title: Predictive value of biomarkers in patients with amnestic mild cognitive impairment
Medical condition: Mild cognitive impairment
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: (No results available)

EudraCT Number: 2014-005389-31

Sponsor Protocol Number: FBB-HUG-2014

Start Date*: 2015-02-18

Sponsor Name:HôPITAUX UNIVERSITAIRES DE GENèVE

Full Title: Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study.

Medical condition: Mild Cognitive Impairment

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	100000004848	10050727	RI scan	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-002606-37	Sponsor Protocol Number: FBB-01-02-15	Start Date*: 2015-09-24
Sponsor Name:Piramal Imaging Ltd
Full Title: Multicenter study to explore the impact of florbetaben (FBB) in change of diagnosis in patients who are evaluated for AD at the CMRR, and are eligible for analysis of CSF according to HAS recommend...
Medical condition: Alzheimer Disease
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: View results

EudraCT Number: 2020-000986-17	Sponsor Protocol Number: ALZ-801-201ADBM	Start Date*: 2020-09-11
Sponsor Name:Alzheon Inc.
Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)
Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2016-001436-35	Sponsor Protocol Number: COFITAGE2016	Start Date*: 2017-01-06
Sponsor Name:Service of Neurology, CHU Liege
Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population
Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: BE (Completed)
Trial results: (No results available)

EudraCT Number: 2017-001502-15

Sponsor Protocol Number: 2016-01382

Start Date*: 2017-12-13

Sponsor Name:Insel Gruppe AG - Inselspital

Full Title: Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Op...

Medical condition: Patients presenting with acute myocardial infarction (non-ST-elevation myocardial infarction or acute ST-elevation myocardial infarction) and with elevated cholesterol levels.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004849	10028597	Myocardial infarction acute	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed) AT (Completed)

Trial results: View results

EudraCT Number: 2015-001211-13

Sponsor Protocol Number: PRODROMALAD

Start Date*: 2015-11-03

Sponsor Name:OSPEDALE SAN RAFFAELE

Full Title: IMAGING OF NEUROINFLAMMATION AND NEURODEGENERATION IN ALZHEIMER’S DISEASE

Medical condition: mild cognitive impairment and familiar Alzheimer disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	22.1	100000004848	10050727	RI scan	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed)

Trial results: View results

EudraCT Number: 2018-002277-22	Sponsor Protocol Number: AMYPAD-02	Start Date*: 2018-09-12
Sponsor Name:Stichting VUmc
Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im...
Medical condition: Alzheimer's Disease
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Completed) ES (Completed) BE (Completed)
Trial results: (No results available)

EudraCT Number: 2013-000370-30	Sponsor Protocol Number: 20150706	Start Date*: 2015-11-26
Sponsor Name:Norrlands University Hospital
Full Title: Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT
Medical condition: Neuroendocrine tumors
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2020-003515-10

Sponsor Protocol Number: BP41783

Start Date*: 2021-03-09

Sponsor Name:F. Hoffmann-La Roche Ltd

Full Title: A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABET...

Medical condition: Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD) and Treatment Naïve diabetic macular edema (DME)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10015919 - Eye disorders	10015919	Eye disorders	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) PL (Completed) IT (Completed)

Trial results: (No results available)

EudraCT Number: 2016-003288-20

Sponsor Protocol Number: BN29553

Start Date*: 2017-05-07

Sponsor Name:F. Hoffmann-La Roche Ltd.

Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE

Medical condition: Alzheimer’s Disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004852	10001896	Alzheimer's disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) DE (Prematurely Ended) GR (Prematurely Ended) FR (Completed) SE (Prematurely Ended) DK (Completed) IT (Prematurely Ended)

Trial results: View results

EudraCT Number: 2019-000670-37	Sponsor Protocol Number: ESR-17-13332	Start Date*: 2019-05-09
Sponsor Name:Radboud University Medical Center
Full Title: Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736).
Medical condition: Patients with non-small cell lung carcinoma (NSCLC).
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: (No results available)

EudraCT Number: 2021-006639-24	Sponsor Protocol Number: 2020/ABM/01/00080	Start Date*: 2022-10-19
Sponsor Name:The Cardinal Stefan Wyszyński Institute of Cardiology
Full Title: Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM
Medical condition: PeriPartum Cardiomiopathy
Disease:
Population Age: Adults		Gender: Female
Trial protocol: PL (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2018-003473-94	Sponsor Protocol Number: UCL-2016-121	Start Date*: 2019-05-20
Sponsor Name:Cliniques Universitaires Saint-Luc
Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms.
Medical condition: Alzheimer’s disease (AD)
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2020-002329-27

Sponsor Protocol Number: ETLAS-2

Start Date*: 2020-12-10

Sponsor Name:Herlev Gentofte Hospital

Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial.

Medical condition: Cerebral small vessel disease and stroke.

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029205 - Nervous system disorders	10070879	Cerebral small vessel ischemic disease	LLT
	22.1	10029205 - Nervous system disorders	10076994	Lacunar stroke	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: (No results available)

EudraCT Number: 2017-001438-25	Sponsor Protocol Number: VWM1	Start Date*: 2020-04-21
Sponsor Name:VU University Medical Center
Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM)
Medical condition: Vanishing white matter
Disease:
Population Age: Children, Under 18		Gender: Male, Female
Trial protocol: NL (Trial now transitioned)
Trial results: (No results available)

EudraCT Number: 2008-003766-26

Sponsor Protocol Number: 25-12-59

Start Date*: 2009-10-12

Sponsor Name:Southampton University Hospitals NHS Trust

Full Title: The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease

Medical condition: Non alcoholic fatty liver disease (NAFLD). This fatty liver disease may progress to a chronic condition that sometimes deteriorates further to cirrhosis and even liver carcinoma. To date there is n...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10019805 - Hepatobiliary disorders	10031743	Other chronic nonalcoholic liver disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2005-001556-20	Sponsor Protocol Number: SB-480848/026	Start Date*: 2005-11-01
Sponsor Name:GlaxoSmithKline Research & Development Limited
Full Title: Integrated Biomarker and Imaging Study – 2 (IBIS-2)
Medical condition: SB-480848 is under developement as a potential anti-atherosclerosis agent for reduction of major cardiovascular events in high risk patient populations.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Completed) CZ (Completed) DE (Completed) AT (Completed) DK (Completed) ES (Completed)
Trial results: View results

EudraCT Number: 2011-000882-11	Sponsor Protocol Number: NEORAD	Start Date*: 2011-08-16
Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
Full Title: A comparison of blood and tissue biomarkers before and after nephrectomy in the firstline setting with everolimus in patients with locally advanced or metastatic renal cell carcinoma
Medical condition: locally advanced or metastatic renal cell carcinoma - 1st line
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: FR (Completed)
Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Fri May 02 19:18:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA